Phio Pharmaceuticals Corp. (NASDAQ: PHIO)
$4.88
+0.2100 ( +4.50% ) 17.0K
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Market Data
Open
$4.88
Previous close
$4.67
Volume
17.0K
Market cap
$2.32M
Day range
$4.24 - $4.82
52 week range
$4.24 - $29.07
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
def | Proxies and info statements | 7 | May 08, 2024 |
ars | Annual reports | 1 | May 08, 2024 |
pre | Proxies and info statements | 7 | Apr 22, 2024 |
8-k | 8K-related | 15 | Apr 02, 2024 |
10-k | Annual reports | 80 | Apr 01, 2024 |
4 | Insider transactions | 1 | Mar 05, 2024 |
4 | Insider transactions | 1 | Feb 27, 2024 |
4 | Insider transactions | 1 | Feb 22, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
8-k | 8K-related | 12 | Jan 26, 2024 |